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Cellular Bcl-2 family proteins regulate a critical step in the mammalian programmed cell death pathway by modulating mitochondrial
permeability and function. Bcl-2 family proteins are also encoded by several large DNA viruses, including all known gamma herpesviruses,
adenoviruses, and several other unrelated viruses. Viral Bcl-2 proteins can prevent cell death but often escape cellular regulatory mechanisms
that govern their cellular counterparts. By evading the ‘‘altruistic’’ suicide of infected cells, viruses can ensure replication and propagation in
the infected host, but sometimes in surprising ways. Many human cancers and other disorders are associated with viruses that encode Bcl-2
homologs. Here we consider the available mechanistic data for viral compared to cellular Bcl-2 protein function along with relevance to the
virus life cycle and human disease states.
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Programmed cell death that is triggered by virus-infected
cells can prevent completion of the viral replication cycle
and the production of progeny virus that would otherwise
spread to adjacent cells in the host. This mechanism may
serve to protect lower organisms that lack cellular immune
systems and that must rely on alternate defense mechanisms
to fight off infections. Mammals also utilize programmed
cell death to control virus infections, but the apoptotic
response to viruses and other pathogens is complex and
frequently even contributes to pathogenesis. Infected cells
initiate programmed cell death internally by sensing the
effects of virus intrusion, such as virus-induced activation
of the cell cycle, but death of infected cells can also be
initiated externally by components of both the innate and
adaptive immune responses such as death receptor signaling
or in some cases by virus binding to its host cell receptor
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tate-directed proteases called caspases that are primary
effectors of mammalian apoptosis. In many cell types,
however, caspase activation is launched by first releasing
mitochondrial factors that catalyze formation of the cas-
pase-activating apoptosome complex or that antagonize
inhibitors of apoptosis proteins (IAPs) [2]. Inevitably,
viruses have adapted numerous ways of circumventing this
host response, including expression of soluble death recep-
tor decoys, regulation of endogenous host death receptors
and ligands, expression of inhibitors of caspase activation
and activity, regulation of host Bcl-2 proteins, and, notably,
expression of viral homologs of Bcl-2 [3–5].
In the nearly 20 years following the discovery of Bcl-2,
the number of known mammalian family members has
mushroomed and Bcl-2 family proteins are now defined
by inclusion of at least one of four distinct Bcl-2 homology
(BH) domains and the variable presence of a putative
membrane-spanning region at the C-terminus [6]. Thus,
the Bcl-2 family is a collection of proteins that generally
share low amino acid sequence similarity. Cellular Bcl-2
family proteins with two or more BH domains are classified
as anti-death (Bcl-2, Bcl-XL) or pro-death (Bax, Bak). A
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single 9–12-amino-acid motif resembling the BH3 domain
of other family members. The three-dimensional structure is
known for only one of the cellular BH3-only proteins, Bid.
Although Bid lacks significant overall amino acid sequence
similarity to other Bcl-2 proteins, its three-dimensional
structure exhibits the conserved Bcl-2 fold. However, it is
not currently known if all of the proteins now classified as
BH3-only Bcl-2 family proteins will also share structural
similarity. Nevertheless, the BH3 domain of Bid is impor-
tant and in some cases sufficient to trigger death. Obvious
homologs of Bcl-2 are conserved in species ranging from
nematodes (Caenorhabditis elegans) to humans, and Bcl-2
overexpression can protect against cell death in yeast and
plants, suggesting a universal, highly conserved ability to
regulate cell survival. Thus, it is not surprising that viruses
have adapted this mechanism to control host cell death and
promote propagation in the host. The finding that all
sequenced gamma herpesviruses encode at least one homo-
log of Bcl-2 implies that these proteins play an indispens-
able role in the virus life cycle. Recognizable Bcl-2
homologs are also encoded by at least one avipoxvirus
(fowlpox), asfivirus (African swine fever) and alpha her-
pesvirus (Marek’s disease-like).
The best studied viral Bcl-2 family member is E1B 19K
of adenoviruses [4]. Using E1B 19K as a query, a blastp
search against the nonredundant database at the National
Center for Biotechnology or more sensitive searches using
PSI-BLAST [7] and a library of hidden Markov models at
Pfam [8] do not reveal homology between E1B 19K and
Bcl-2 proteins. Pairwise alignments of E1B 19K with viral
Bcl-2 proteins [such as Kaposi’s sarcoma virus Bcl-2
(KSbcl-2)], as well as database searches with putative BH
domains, reveal expect values that are not statistically
significant. While it is thus unlikely that E1B 19K and
Bcl-2 proteins share a common ancestor (a definition of
homology), it is clear that they share similar anti-apoptotic
functions [9]. On this basis E1B 19K is often referred to as a
functional ‘‘homolog’’ of Bcl-2. In addition, determination
of the three-dimensional structure may ultimately reveal a
folded structure similar to Bcl-2. Human cytomegalovirus
(beta herpesvirus) also has incorporated a Bcl-2-like func-
tion into its genome (vMIA), indicating that the advantage
conferred to gamma herpesviruses by viral Bcl-2 is probably
not unique [10]. Here we use the term homolog to refer only
to the group of viral Bcl-2 family proteins with obvious
amino acid sequence similarity.
Bcl-2, the founding member of the Bcl-2 family of death
regulators, was originally identified as an oncogene at
t(14;18) translocation chromosomal breakpoints that occur
in follicular B cell lymphomas and result in Bcl-2 over-
expression [11–13]. Bcl-2 (B cell lymphoma-2) represented
a new type of oncogene that appeared to promote tumor
formation primarily through the extension of cell survival
rather than increased cell proliferation [14–17]. Nucleotide
sequence analysis revealed sequence similarity to a previ-ously identified gene encoded by Epstein–Barr virus (EBV)
called BHRF1 [18] and BHRF1 was subsequently shown to
inhibit cell death [19]. Whether viral Bcl-2 homologs
contribute to oncogenesis in humans in an analogous
fashion to cellular Bcl-2 is not yet known but remains a
possibility in several virus-associated tumors.2. How do Bcl-2 proteins modulate the death pathway?
An understanding of how viral Bcl-2 proteins function to
inhibit apoptosis and promote the virus life cycle necessi-
tates examination of how host Bcl-2 family proteins regulate
cell death. Although considerable progress has been made in
recent years, the precise biochemical mechanisms by which
any Bcl-2 family protein inhibits cell death are still un-
known and remain the subject of lively debate. The first clue
came with the identification of Bcl-2-associated X protein,
Bax, that was originally suggested to heterodimerize with
Bcl-2 [20]. This led to the proposal of the ‘‘rheostat’’ model
of cell survival where the ratio of anti-apoptotic to pro-
apoptotic Bcl-2 family members of a cell receiving a death
stimulus ultimately determines cell fate [21]. The signifi-
cance of direct binding interactions between Bax and Bcl-2
or Bcl-XL in vivo has been called into question because of
detergent effects on heterodimer formation [22], non-over-
lapping intracellular localizations of Bax and Bcl-2 [22],
and the ability of Bcl-XL mutants deficient in Bax-binding
to inhibit apoptosis [23]. Nevertheless, the pro-apoptotic
functions of Bax and its relative Bak are suppressed by the
anti-apoptotic Bcl-2 proteins when co-expressed in cells. In
fact, Bax and Bak have been suggested to be the primary
targets (direct or indirect) of viral Bcl-2 homologs, but this
has not been rigorously demonstrated in physiological
settings. However, extensive analysis of adenovirus E1B
19K indicates functional interactions with Bax and Bak as
detailed below [4].
The second major clue to the biochemical function of
Bcl-2 family members followed from the discovery that the
release of mitochondrial cytochrome c was important for
apoptotic cell death [24]. Bcl-2 was found to inhibit cyto-
chrome c release [25,26] while Bax directly promoted
cytochrome c release from isolated mitochondria [27,28].
Understanding how Bax initiates cytochrome c release and
how Bcl-2 inhibits release therefore also becomes important
for assessing the anti-death function of viral Bcl-2 relatives.
Activation of the pro-death activity of Bax and Bak can be
achieved by the BH3-only molecule Bid once Bid has been
activated by proteolysis [29–33], as well as by other means
that are still under investigation. Oligomerization of at least
four Bax molecules in the mitochondrial outer membrane is
likely a process critical for the ability of Bax (and presum-
ably Bak) to induce membrane permeabilization; however,
the importance of very large ( = 260 kDa) oligomeric com-
plexes of Bax that have been observed in apoptotic cells for
the permeabilizing activity is still in question [34–36].
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function of Bcl-2 and Bcl-XL is related to their ability to
heterodimerize with Bax and Bak, thereby preventing Bax/
Bak homo-oligomerization and the release of cytochrome c,
mutants of Bcl-XL incapable of binding Bax or Bak are still
capable of inhibiting apoptosis [23]. Those Bcl-XL mutants
retain the ability to bind truncated Bid (tBid) [37] and
another BH3-only protein Bad [38], prompting a revision
of the heterodimerization model to suggest that the seques-
tration of BH3-only death ligands rather than of Bax and
Bak death effectors was the primary mechanism of protec-
tion by anti-apoptotic Bcl-2 proteins (Fig. 1A) [37]. A
genetic knockout approach demonstrated that Bax and
Bak are indeed downstream of BH3-only molecules in the
programmed cell death cascade and essential for apoptosis
in response to multiple death stimuli [37,39,40]. A variation
of this heterodimerization model supported by Strasser and
colleagues suggests that BH3-only protein binding to Bcl-2
and Bcl-XL negates an inherent anti-apoptotic function ofFig. 1. Two models for the inhibition of Bax and Bak pro-apoptotic activity
by anti-apoptotic Bcl-2 proteins. In both models, an active BH3-only
molecule such as tBid initiates a sequential conformational change in Bak
(or Bax) exposing the N-terminus followed by the C-terminus. For clarity,
Bcl-2 and Bak are the examples used in the figure, but in these hypothetical
models, Bak can be replaced by Bax, and Bcl-2 is representative of all anti-
apoptotic proteins thought to function like Bcl-2. In (A), Bcl-2 does not
interact with Bak but prevents BH3-only proteins from initiating the
conformational change in Bak that leads to oligomerization and
mitochondrial outer membrane permeabilization. In (B), Bcl-2 does not
interact with Bak in the absence of an apoptotic stimulus, but following
BH3 protein-induced conformational changes in Bak, Bcl-2 can bind the
‘‘active’’ conformations of Bak, preventing it from oligomerizing and
increasing mitochondrial outer membrane permeability. In keeping with this
model, the adenovirus Bcl-2 functional homolog E1B 19K does not interact
with Bax unless an N-terminal conformational change first occurs.
However, unlike cellular Bcl-2, E1B 19K cannot interact with tBid,
although E1B 19K has been found to interact with other BH3-only proteins
that may serve a similar role. The red arrow in each model indicates the step
in the pathway that is blocked by Bcl-2.these molecules, rather than masking a pro-apoptotic func-
tion of the BH3-only molecule (Fig. 1B). One proposal for
this constitutive anti-death activity of Bcl-2 and Bcl-XL was
to hold Bax and Bak in check, however, the mechanism by
which this could potentially occur was clouded by the
failure to observe stable Bax/Bak-Bcl-2/Bcl-XL interactions
in healthy cells.
Recent evidence in which chemical cross-linkers reveal
that cellular Bcl-2 has a preferred affinity for an N-termi-
nally-modified ‘‘active’’ conformation of Bak over a Bid
BH3 peptide has prompted the revisiting of this idea that the
primary function of Bcl-XL and Bcl-2 is to hold Bax and
Bak in check (Fig. 1B) [41]. This finding is reminiscent of
the observation that adenovirus E1B 19K binds Bax only
after Bax has undergone an N-terminal shift in conformation
[42–45]. According to this revised model, an upstream
signal such as tBid induces a conformational change in
Bak (and presumably Bax) at the N-terminus that may
precipitate a similar change in neighboring Bak molecules,
leading to auto-oligomerization [41]. In this model, anti-
apoptotic Bcl-2 inhibits oligomerization of Bak by binding
the active Bak conformer, but this inhibition can be relieved
if the concentration of BH3 death ligands is sufficiently
high to sequester Bcl-2 away from Bak. The requirement of
a conformational change for the interaction between Bak
and Bcl-2 could explain why previously such interactions
between Bax or Bak and antiapoptotic Bcl-2 family mem-
bers were seen only in the presence of nonionic detergents
[22,46].
It is important to note that the two models (Bax/Bak
binding to Bcl-2 vs. Bax/Bak binding to BH3-only mole-
cules that are ‘‘sequestered’’ by Bcl-2) are not mutually
exclusive. Thus, cellular and viral Bcl-2 and perhaps other
viral anti-apoptotic proteins could act both by inhibiting
Bax/Bak and by sequestering BH3-only death molecules.
Additionally, BH3-only proteins likely have roles in cell
death that are independent of their ability to promote Bax/
Bak activation that may also require opposition, such as the
ability of tBid to alter inner mitochondrial membrane
structure [47]. Because the majority of yeast two-hybrid,
co-immunoprecipitation, and GST pull-down data on viral
Bcl-2 protein interactions with host family members has
focused on Bax and Bak over BH3-only molecules, it is
difficult to conclude that viral Bcl-2 proteins primarily target
the core apoptotic machinery rather than their upstream BH3
activators. For example, E1B 19K binds both BH3-only
proteins (Bik [48,49] and Nip proteins such as BNIP3 [50])
and Bak [51] and activated Bax [52,53], while some viral
Bcl-2 proteins often fail to bind Bax or Bak even in the
presence of nonionic detergents. Thus, data for adenovirus
E1B 19K favor the model of primarily targeting the core
mitochondrial permeability regulators Bax and Bak for its
mechanism of protection, but the role of heterodimerization
with pro-apoptotic cellular Bcl-2 family members in pro-
tection by the herpesvirus and other viral Bcl-2 homologs
remains largely untested.
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of Bcl-2 family proteins was provided by three-dimensional
structure determination. Bcl-XL was found to have structural
similarity to the B domains of bacterial toxins such as
diphtheria toxin and colicins, which can form pores in lipid
membranes and translocate toxin A domains across the
membrane [54]. Both anti- and pro-apoptotic Bcl-2 family
members form channels in artificial membranes [34,55–62]
and modulate channels formed by the reconstituted mito-
chondrial proteins, adenine nucleotide translocator (ANT)
[63] and voltage-dependent anion channel (VDAC), when
added to membranes [64,65]. In the case of pro-apoptotic
Bax and Bak, mitochondrial outer membrane channel for-
mation has been proposed to mediate the release of inter-
membrane space proteins that have roles in apoptosis (e.g.
cytochrome c, Smac/DIABLO, and AIF), although whether
a protein or lipidic pore is responsible is still in question
[2,66]. An alternative hypothesis suggests that Bax may
contribute to activation of a mitochondrial inner membrane
channel called the permeability transition pore that releases
intermembrane proteins through matrix swelling and con-
comitant outer membrane rupture [63,67,68]. Thus, while
the evidence for Bax/Bak-mediated release of mitochondrial
proteins to promote death in apoptosis is now overwhelm-
ing, the biochemical mechanism by which Bax and Bak
accomplish this feat is undefined and may differ among cell
types and death stimuli (recently reviewed in Ref. [2]). In
addition, a fraction of Bax and Bak proteins that localize to
the endoplasmic reticulum (ER) was found to alter the
steady-state level of ER calcium that, when released fol-
lowing a death stimulus, contributed to cell death [69,70].
Even more complicating is the observation that Bax and/or
Bak functions as potent inhibitors of apoptotic neuronal
death in mouse models of seizure and virus-induced en-
cephalitis [71,72]. The ability of Bak to reduce neuronal
excitability together with the observation that Bcl-XL can
enhance neuronal excitability suggest that the ability of Bcl-
2 family proteins to regulate synaptic responses may con-
tribute to their reversed phenotype in some neuron subtypes
[72,73].
The function of channels formed by anti-apoptotic Bcl-2
proteins in the context of cell death is more opaque than for
the pro-death family members Bax and Bak. The a5 and a6
helices of Bcl-2 were required for pore formation in artificial
membranes and for protection against Bax-induced death,
but not for Bax binding (via the tail of hydrophobic tail of
Bcl-2), suggesting that channel formation may play a role in
the anti-apoptotic mechanism of Bcl-2 [61,74]. A reduction
in mitochondrial outer membrane permeability to ATP
occurs in growth factor withdrawal-induced apoptosis that
is rescued by Bcl-XL or Bcl-2 overexpression [75]. That is,
Bcl-XL is suggested to maintain the flow of ATP into the
cytosol following a death stimulus. Whether this reduction
in permeability is a general feature of apoptosis and how it
contributes to cell death progression remain to be deter-
mined. A further link between Bcl-2 family proteins andmetabolism comes from the finding that the BH3-only
protein Bad is required for assembly of a complex contain-
ing glucokinase at mitochondria [76]. Mice deficient for
Bad lack this complex and exhibit characteristics of diabetes
[76]. Thus, Bcl-2 family proteins likely have multiple
biochemical functions/interactions, and these independent
functions are difficult to study in isolation.3. Structure and dimerization of Bcl-2 proteins
Analysis of the structure of Bcl-XL complexed to a Bak
BH3 peptide revealed that the BH1, BH2, and BH3 domains
of Bcl-XL surround a hydrophobic cleft that enables the
binding of an a-helical BH3 domain of a binding partner
[77]. Mutations in the BH1 and BH2 domains of Bcl-2 can
abrogate its ability to interact with Bax and protect against
apoptosis, indicating the importance of these domains for
anti-death activity [78]. Mutation of the homologous BH1
residue in the African swine fever virus homolog LMW5-
HL/A179L and BH1 and BH2 mutations in EBV BHRF1
also nullified anti-death activity, suggesting functional con-
servation between viral and cellular BH1 and BH2 domains
[79,80]. Not all BH1 mutants lose the ability to protect,
however, a BH1 mutant of Bcl-XL retains the ability to bind
tBid and inhibit apoptosis despite the loss of Bax binding
[23,37]. The importance of the BH1 and BH2 domains of
viral Bcl-2 homologs for their binding interactions with
Bax/Bak vs. BH3-only molecules has yet to be fully tested.
All viral Bcl-2 structural homologs contain a recognizable
BH1 domain and with the exception of gHV68 Bcl-2, a
BH2 domain [5]. However, the BH3 and BH4 motifs are
poorly conserved, possibly indicating that these domains are
less important for anti-apoptotic activity, or that these
modified viral domains possess novel functions. Three-
dimensional structure determination of E1B 19K is expected
to confirm that this protein has domains that are positionally
analogous to BH1 and BH2.
The three-dimensional structure of KSBcl-2 revealed
overall structural similarity to the Bcl-2 family proteins
Bcl-XL, Bcl-2, Bcl-w, Bax, and Bid, even in domains where
the primary amino acid sequence is not conserved [54,81–
86]. The reason that certain Bcl-2 family members (e.g.
Bax) behave largely as pro-apoptotic proteins while others
(e.g. Bcl-XL) are predominantly anti-apoptotic despite gross
structural similarity is unclear but may be related to their
propensity to form large oligomeric complexes [87]. The a-
helices 5 and 6 that are required for Bcl-2 pore formation
[61,74] are preserved in the KSBcl-2 structure, suggesting
that like Bcl-2, KSBcl-2 might also form pores in mem-
branes, although this has yet to be tested. As was the case
for the three-dimensional structure of Bcl-XL bound to a
BH3 peptide of Bak, the BH1-BH2 domains together with
the alpha helix corresponding to BH3 in the KSBcl-2
protein are involved in binding a BH3 peptide derived from
Bak [81]. In contrast to Bcl-XL, however, which displays
Fig. 2. Inhibition of tBid-induced cytochrome c release by recombinant
human Bcl-XL but not recombinant EBV BHRF1. Isolated brain
mitochondria (0.5 mg/ml) were incubated in the presence of 125 mM
KCl, 2 mM Pi, 20 mM HEPES, pH 7.0 with added 5 mM malate, 5 mM
glutamate, 4 mM MgCl2, 3 mM ATP, and 1 mM ADP at 30jC. 50 nM tBid
was used to stimulate cytochrome c release in the presence and absence of
500 nM Bcl-XL, BHRF1, or GST control and released cytochrome c was
immunodetected in the supernatant following centrifugation of the
mitochondrial suspension. Mitochondrially associated EBV BHRF1 was
detected by immunoblotting of pellets following centrifugation. No BHRF1
was detected in the supernatant.
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(Kd = 0.6 nM vs. Kd = 3,900 nM for KSBcl-2), KSBcl-2 was
much more proficient in binding Bak BH3 (Kd < 50 nM vs.
Kd = 480 nM for Bcl-XL) and to a lesser extent Bax BH3
(Kd = 980 nM vs. Kd = 13,000 nM for Bcl-XL) [81,82,88].
This predicted binding specificity of KSBcl-2 for Bcl-2
proteins supports the concept that viral Bcl-2 proteins target
the pivotal death effectors Bax and Bak rather than tissue
and death stimuli-specific BH3 molecules for their inhibi-
tory action. However, no interaction between KSBcl-2 and
Bax or Bak was detected using in vitro translated proteins
[89]. These findings could be reconciled if a conformational
change in Bak or Bax is required for interaction with
KSBcl-2 as was the case for the interaction between Bax
and adenovirus E1B 19K [42–45]. Another reasonable
possibility is that that the C-terminal alpha helix of
KSBcl-2 is folded into the hydrophobic BH3-binding cleft
as was found for Bax [84] and Bcl-w [85,86]. This C-
terminal tail would need to be released to reveal the
hydrophobic binding pocket and enable interactions with
partner proteins. Unlike KSBcl-2, the herpesvirus saimiri
Bcl-2 homolog ORF16 interacts with both Bax and Bak in
GST pull-down assays [90].
In contrast to KSBcl-2 and cellular Bcl-2, the solution
structure of EBV BHRF1 revealed that although the gern-
eral alpha-helical folds typical of Bcl-2 family members
were conserved in this viral protein, the prominent binding
groove found in the cellular Bcl-2 homologs was absent
[91]. Notably, three nonpolar residues found in the groove
of Bcl-XL and KSBcl-2 that are believed to contact a bound
Bak BH3 peptide are replaced by polar residues in BHRF1.
In this respect, BHRF1 may be more like Bid, which also
lacks the deep cleft present in other family members [92].
Consistent with the absence of a hydrophobic BH3-binding
pocket, BHRF1 did not bind Bak, Bax, or Bad BH3
peptides and bound to a BH3 peptide of Bid only weakly.
However, EBV BHRF1 does bind Bak, but not Bax in GST
pull-down, immunoprecipitation, and yeast two-hybrid stud-
ies [90,93], indicating that the ability to interact with
synthetic BH3 domains may not always be predictive of
the capacity to interact with whole proteins and raising the
possibility that domains other than the BH3 domain of Bak
are important for the observed interaction. Another possible
heterodimerization domain is the BHRF1 hydrophobic tail
(not included in the available structure), which could occupy
the hydrophobic cleft of another family member. Interest-
ingly, we have found that purified recombinant BHRF1, in
contrast to recombinant human Bcl-XL, does not inhibit
tBid-induced cytochrome c release from isolated brain
mitochondria even though BHRF1 associated avidly with
mitochondrial membranes (Fig. 2), supporting the idea that
viral Bcl-2 family members may employ non-heterodimeri-
zation-mediated mechanisms to block tBid and Bax/Bak
function in cells.
Some gamma herpesviruses are difficult to propagate in
cell culture, and the ability of their Bcl-2 homologs to bindendogenous cellular Bcl-2 proteins during productive virus
infections is difficult to assess. However, E1B 19K binds
Bak in adenovirus-infected cells and prevents Bak–Bax
interaction [44]. Despite the various data showing Bax
and/or Bak interaction with viral Bcl-2 proteins, it is
important to note that BHRF1 and KSBcl-2 were potently
protective against Bax-induced cell death in transfected
mammalian cells where stable interactions with Bax were
not observed [94], suggesting that not all protection by viral
Bcl-2 proteins can be explained via stable, direct sequestra-
tion models and additional mechanisms of anti-apoptotic
activity remain to be discovered.4. Posttranslational regulation of Bcl-2 family proteins
The composition and function of Bcl-2 proteins subcat-
egorize them into three classes according to conventional
dogma: (1) Multi-domain proapoptotic proteins (e.g. Bax
and Bak), (2) multi-domain anti-apoptotic proteins (e.g. Bcl-
XL and Bcl-2), and (3) BH3 domain-only pro-apoptotic
proteins (e.g. Bid and Bim). This conventional view has
been challenged, however, by the findings that ‘‘anti-apo-
ptotic’’ Bcl-2 and Bcl-XL have latent pro-death activity that
is activated by protease-mediated removal of the N-terminus
[95,96] and that ‘‘pro-apoptotic’’ Bax and Bak display
potent anti-death activity under some circumstances
[71,72,97]. A revised model suggests that all Bcl-2 family
proteins are inherently pro-survival (or neutral) with respect
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olysis, phosphorylation, conformational changes or other) to
uncover their pro-apoptotic function [5].
Cleavage of Bcl-2 and Bcl-XL is not merely a fortuitous
byproduct of caspase activation but is important for inacti-
vating the survival function of these proteins to ensure cell
death and in some cases may play an active role in the death
process [95,96,98–100]. This presents a potential conun-
drum for the viral strategy of adapting Bcl-2 function for its
own purposes, since direct caspase activation via death
receptor stimulation by cytotoxic cytokines could nullify
the protective function of viral Bcl-2 homologs. Phosphor-
ylation is also known to impair the anti-apoptotic potency of
Bcl-XL and/or Bcl-2 [101–103], which might potentially
target viral Bcl-2 as well. Viral Bcl-2 proteins have circum-
vented this problem, in part, by streamlining to include
apparently the minimal domains required for protection
while largely minimizing regulatory regions such as the
loop domain between BH4 and BH3 that in their cellular
counterparts is subject to phosphorylation and proteolysis
(Fig. 3A). Out of six gamma herpesvirus Bcl-2 homologs
tested, Kaposi’s sarcoma-associated herpesvirus (KSHV)/
human herpesvirus 8 Bcl-2 (KSBcl-2), g-herpesvirus 68
(gHV68) Bcl-2, herpesvirus saimiri (HVS) Bcl-2, EBV
BHRF1 and BALF1, and bovine herpesvirus 4 (BHV4)
Bcl-2, only gHV68 Bcl-2 could be cleaved by recombinant
caspase-3 or apoptotic cell extracts (Fig. 3B), suggesting
that with the exception of gHV68 Bcl-2, viral Bcl-2 proteins
are resistant to this mechanism of inactivation [94,104].Fig. 3. Posttranslational modification of host vs. viral Bcl-2 family proteins.
(A) Cellular Bcl-2 family members (i.e. Bcl-XL) are subject to posttransla-
tional modifications such as proteolysis and phosphorylation within the
regulatory loop region that can inactivate anti-apoptotic and uncover latent
pro-death activity. (B) Viral Bcl-2 homologs are resistant to inactivation by
cleavage and have largely eliminated latent pro-apoptotic activity, perhaps
by failing to conserve the BH3 ‘‘death’’ domain.Resistance to proteolysis may be a contributing factor to the
finding that BHRF1 can suppress cell death in some cases
where Bcl-2 is ineffective [80]. Although gHV68 Bcl-2 is
cleaved by caspase-3 and by apoptotic cell extracts, expres-
sion of an engineered ‘‘cleavage’’ product lacking its N-
terminus could not induce apoptosis, indicating that the
latent pro-death activity of Bcl-2 is not retained by the virus.
Even in the absence of proteolysis, it appears that the
latent apoptosis-promoting activity of cellular Bcl-2 can
sometimes be manifested, at least in overexpression assays
[105]. It was therefore of interest to determine whether other
viruses, like gHV68, have also eliminated this masked pro-
apoptotic activity. Expression of other N-terminal truncated
gamma herpesvirus Bcl-2 proteins, with the exception of
DN20 KSBcl-2, failed to induce death of baby hamster
kidney (BHK) cells [104]. This may be due to the observa-
tion that the BH3 ‘‘death’’ domain that is important for the
latent pro-apoptotic activity of Bcl-2 is poorly conserved in
many viral Bcl-2 homologs. Although a C-terminal KSBcl-2
fragment was capable of killing, this fragment is apparently
not generated in healthy or apoptotic cells transfected with
full-length KSBcl-2 even when in the same experiment the
analogous expression of mammalian Bcl-2 results in cleav-
age and apoptosis [104]. Thus, by incorporating and sub-
verting cellular Bcl-2 function to their own advantage,
viruses have eliminated two key features of Bcl-2: inacti-
vation of anti-death function by proteolysis and activation of
latent pro-apoptotic activity. Interestingly, a cyclin homolog
of Kaposi’s sarcoma-associated herpesvirus directs cyclin-
dependent kinase 6 (cdk6) to phosphorylate and inactivate
host Bcl-2 while leaving the function of KSBcl-2 unaffected
[102], indicating that there may be additional reasons why
viruses have adopted their own Bcl-2 homologs rather than
making exclusive use of cellular proteins [106].5. Role of viral Bcl-2 in virus replication and associated
disease
While understanding the biochemical interactions and
viral functions of Bcl-2 proteins is of fundamental impor-
tance, the larger picture regarding their role in the virus life
cycle and associated diseases is even more complex. Evi-
dence discussed in detail below points to functions for
various family members in facilitating replication, reactiva-
tion from latency, and virus-associated tumorigenesis (Fig.
4). Several human tumors are associated with KSHV that
expresses KSBcl-2 and with EBV that expresses BHRF1
and BALF1, but a potential role for these viral Bcl-2
homologs in human disease remains highly speculative in
the absence of good animal models to address this question.
The best evidence for an in vivo role for a viral Bcl-2 family
member in pathogenesis arose from the study of murine
gHV68 mutants with a disrupted gHV68 Bcl-2 gene.
Although adenoviruses are not known to cause human
tumors, the more tractable cell culture models with which
Fig. 4. Role of viral Bcl-2 in the virus life cycle. E1B 19K promotes acute
replication by inhibiting apoptosis and preventing premature death of the
infected cell. gHV68 Bcl-2 is suggested to promote reactivation from
latency and persistent replication but has not been shown to play a role in
acute replication or the establishment of latency. Further research is needed
to elucidate the role of persistent replication in the gamma herpesvirus life
cycle and associated disease states. KSBcl-2 and BHRF1 are speculated to
participate in the tumorigenesis associated with their respective viruses by
analogy to the function of Bcl-2 in follicular lymphomas and its
conservation in clinical isolates, but because of the lack of good animal
models this hypothesis has yet to be tested. Although E1B 19K can
cooperate with adenovirus E1A in cell transformation, adenovirus
infections are not associated with human cancers.
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role for apoptosis in limiting viral replication and have
elucidated host biochemical death pathways that respond
to virus infection [44,107]. Adenoviruses have also served
as a powerful model in which to study the role of anti-
apoptotic E1B 19K in cellular transformation.
5.1. cHV68 Bcl-2
A Bcl-2 homolog is encoded by the M11 open reading
frame of murine gHV68 [108]. gHV68 Bcl-2 (also referred
to as M11) has a recognizable BH1 domain and hydropho-
bic C-terminal region, but lacks defined BH2, BH3 and
BH4 domains [4,5,104,108,109]. Like cellular anti-apopto-
tic Bcl-2 proteins in some cell types, gHV68 Bcl-2 is
protective against many death stimuli including Sindbis
virus infection, Fas ligation and tumor necrosis factor a
(TNF-a) treatment [104,109,110]. Surprisingly, despite the
presence of a putative C-terminal transmembrane domain
and in contrast to mammalian Bcl-2, hemagglutinin (HA)-tagged gHV68 Bcl-2 protein was predominantly cytoplas-
mic in transfected HeLa cells [109]. It is possible that the
HA tag influences intracellular localization or that localiza-
tion is influenced by the expression of other gHV68
proteins. However, it is also possible that gHV68 Bcl-2
has a non-mitochondrial site of action. The EBV Bcl-2
homolog BALF1 is also cytosolic [94], and mammalian
Bcl-XL is partially localized to the cytosol [111], supporting
the notion that Bcl-2 family proteins have cytoplasmic
targets in addition to their known activities at mitochondria
and ER. Consistent with this idea, gHV68 Bcl-2 as well as
BALF1, BHRF1, KSBcl-2 and Bcl-XL bind the novel cell
death regulator Aven that interacts with components of the
apoptosome (Ref. [112] and DS Bellows, P Irusta, and JM
Hardwick, unpublished observations).
gHV68 Bcl-2 mRNA had been detected both early in
lytic/replicative infection cycle and in latently infected
tissues [110,113], but until recently, any participation of
gHV68 Bcl-2 in lytic replication and the establishment of
latency was unknown. To address the function of viral Bcl-
2 in the virus life cycle, recombinant gHV68 viruses
lacking their Bcl-2 homolog were tested in an animal model
to provide the first evidence that viral Bcl-2 plays a role in
vivo [114]. Two independent mutant viruses were generated
with premature stop codons in the gHV68 Bcl-2 gene,
precluding translation of the majority of the sequence,
including both the BH1 domain and hydrophobic C-termi-
nal tail. Contrary to expectations, viral Bcl-2 was inconse-
quential to lytic replication as no differences in virus
replication were observed in the spleen or liver during
acute infection of mice with wild-type gHV68 vs. the
mutant Bcl-2 viruses. Similar results were obtained in
immunocompromised interferon-g-deficient (IFN-g /)
mice [114]. These results are surprising in that inhibition
of apoptosis is thought to promote acute replication by
delaying the death of infected host cells. However gamma
herpesviruses are known to encode multiple inhibitors of
apoptosis, so it may be that gHV68 Bcl-2 is functionally
redundant.
Subsequent to acute infection, gamma herpesviruses
enter a latent state in which the viral genome exists as a
circular episome. During latency a distinct subset of genes
is transcribed. Since gHV68 Bcl-2 mRNA was detected in
latently infected tissues, it is possible that gHV68 Bcl-2
might play a role either in the establishment of or re-
emergence from latency. A functional gHV68 Bcl-2 was
not required for the virus to establish latency in peritoneal
cells or splenocytes [114]. However, gHV68 Bcl-2 mutant
viruses exhibited significantly impaired ex vivo reactiva-
tion from latency in peritoneal cells in both wild-type and
IFN-g / mice, displaying a four- to fivefold reduction in
reactivation efficiency compared to wild-type gHV68 virus.
Gamma herpesvirus can also persistently replicate in cells
independent of a true latent state and it has been speculated
that persistent replication may occur following reactivation
from latency. Consistent with the role of viral Bcl-2 in
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mice infected with Bcl-2-deficient gHV68 showed signif-
icantly impaired persistent replication in contrast to wild-
type virus, demonstrating that gHV68 Bcl-2 is required for
viral persistence. Persistent replication of gHV68 in
smooth muscle cells of chronically infected IFN-g /
and IFN-g receptor (IFN-g R) / mice leads to severe
large vessel vasculitis and death [115,116]. Because of the
finding that gHV68 Bcl-2 is required for persistent repli-
cation, gHV68 Bcl-2 mutant viruses are predicted to
display decreased virulence in this model of chronic
disease. This was indeed the case, with IFN-g R / mice
chronically infected with gHV68 Bcl-2 mutant virus exhib-
iting approximately threefold greater survival than mice
infected with virus containing functional gHV68 Bcl-2
[114]. A corresponding decrease in the incidence of arter-
itic lesions (74% to 28%) was also observed. Consistent
with the absence of a role for gHV68 Bcl-2 in acute
infection, no reduction in virulence was observed in a
mouse model of acute lethal meningitis or in a recombi-
nation activating gene 1 (RAG-1)-deficient mouse model of
acute disease following infection with the mutant gHV68
Bcl-2 virus [114]. Although tumors in mice infected with
gHV68 have been observed on rare occasions, gHV68
does not appear to be tumorigenic in mice. Therefore,
while this mouse g-herpesvirus is a valuable tool to study
pathogenesis, a model that mimics the g-herpesvirus-asso-
ciated tumors in humans is still lacking.
Several important implications arise from this study of
gHV68 Bcl-2 function in vivo. First, the specific role of
gHV68 Bcl-2 in persistent but not acute replication
implies that persistent replication is a genetically distinct
process from replication during acute infection in that
different viral proteins are involved. gHV68 cyclin was
similarly shown to be important for ex vivo reactivation
from latency and persistent replication but not for acute
replication [114,117]. Second, cell cycle progression is
likely required for ex vivo reactivation from latency and
gHV68 Bcl-2 may be important for preventing apoptosis
induced by either viral cyclin or a host response to cell
cycle activation. Such a relationship has been reported for
Kaposi’s sarcoma-associated herpesvirus, where expression
of KSBcl-2 blocks apoptosis induced by overexpression of
KSHV viral cyclin [118]. gHV68 viral cyclin is oncogenic
and promotes cell cycle progression in primary lympho-
cytes despite causing increased apoptosis [119], suggesting
that gHV68 Bcl-2 might be needed to lead to efficient
immortalization in an analogous fashion to the coopera-
tivity observed between c-myc and cellular Bcl-2 [17,120].
Third, persistent replication likely contributes to spread of
virus within the population and it has been suggested that
it may contribute to tumorigenesis by g-herpesviruses
[114,121]. Therefore, gHV68 Bcl-2 may indirectly contrib-
ute to tumorigenesis because of its importance in persistent
replication even if it lacks overt oncogenic activity. Finally
and most significantly, this study conclusively identifies arole of viral Bcl-2 in the virus life cycle and an associated
disease state.
5.2. EBV BHRF1 and BALF1
EBV BHRF1 was the first viral Bcl-2 homolog to be
identified [18]. Similar to the C-terminal hydrophobic tail of
Bcl-2, the C-terminal region of BHRF1 targets the protein to
intracellular membranes, including the mitochondrial outer
membrane [122–124]. In keeping with other anti-apoptotic
Bcl-2 proteins, BHRF1 is protective against many death
stimuli, including serum deprivation and calcium ionophore
treatment in B lymphocyte cell lines [19], death receptor
signaling [125–127], DNA damaging agents [128], and
Sindbis virus infection [90].
EBV encodes a second Bcl-2 homolog originally dubbed
BALF1 [129]. Later it was recognized that translation of the
BALF1 mRNA is likely initiated from the second in-frame
methionine (probably the first methionine in the mRNA
transcript) that, in contrast to the first methionine, is
conserved in the BALF1 reading frame of several primate
lymphocryptoviruses [94]. The original longer BALF pro-
tein was renamed BALF0 and the protein product resulting
from translation at the internal methionine was subsequently
referred to as BALF1. Overexpressed BALF0 was initially
reported to confer anti-apoptotic activity [129]. However,
using similar or alternate strategies, we have been unable to
detect significant anti-death activity with either BALF0 or
BALF1 [94]. Although BALF1 is more distantly related to
cellular Bcl-2, the conservation of BALF1 in a wide range
of gamma herpesviruses indicates that BALF1 has a critical
function presumably related to control of cell death though
other possibilities remain. The only function of BALF1
uncovered thus far is its ability to negate the anti-apoptotic
activity of the other EBV viral homolog BHRF1 as well as
the viral protein KSBcl-2 but not cellular Bcl-XL. Although
BALF1 and BHRF1 heterodimers can be detected in cell
lysates containing detergents, distinct intracellular localiza-
tion patterns were observed by immunofluorescence in both
healthy and dying cells, with BALF1 exhibiting diffuse
cytosolic staining in contrast to the punctate mitochondrial
localization of BHRF1 [94]. Therefore, BALF1 may inhibit
the anti-death activity of BHRF1 without direct physical
interaction.
A role for either BHRF1 or BALF1 in EBV infections
has yet to be reported. BHRF1 is expressed during the
productive/lytic replication cycle [123,130]. Although latent
cycle transcripts that contain the BHRF1 open reading
frame have been reported [122,131,132], the encoded pro-
tein has not been convincingly detected in latently infected
cells. It has been postulated that like adenovirus E1B 19K,
BHRF1 may function in EBV infections to promote viral
replication by preventing premature death of the host cell
[4,5]. BHRF1 can functionally substitute for E1B 19K in
preventing apoptosis induced by infection with an adenovi-
rus mutant that lacks this protein [128] and apoptosis is
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However, initial studies with mutant EBV viruses lacking
intact BHRF1 did not display any impairment in infection
and replication in B cell lymphocytes and cell lines in vitro
[133,134], consistent with in vivo results obtained with
gHV68 virus deficient in viral Bcl-2 [114]. The lack of a
phenotype for BHRF1 ablation may be due to redundancy
of anti-apoptotic function encoded by the virus. Alterna-
tively, the finding that EBV does not efficiently enter lytic
cycle replication in cultured cells has hampered efforts to
delineate the role of BHRF1 in the virus life cycle. New
methods have been developed by Hammerschmidt and
colleagues to engineer mutations in EBV genomes and to
study their effects in culture. These approaches are likely to
provide new information about the functions of BHRF1 and
BALF1 during infection. However, the lack of a good
animal model to study EBV pathogenesis remains an
obstacle to progress. An important role for BHRF1 in the
EBV life cycle is predicted from the finding that BHRF1 is
conserved at both the sequence and functional level in a
wide range of primary EBV isolates [80]. It may be that
BHRF1, like its gHV68 homolog, is involved in reactiva-
tion from latency or persistent replication, processes diffi-
cult to model in vitro. One could speculate that BALF1
allows the virus to fine-tune the regulation of host cell
apoptosis so that later in the lytic cycle when death is
potentially advantageous to promote the spread of progeny
virus, the function of BHRF1 can be eliminated by BALF1.
EBV is closely associated with several tumors of both
lymphoid and epithelial origin, including Burkitt’s lympho-
ma, B-lymphoproliferative disease, Hodgkin’s lymphoma,
some T-cell lymphomas, nasopharyngeal carcinoma and
stomach cancers [135,136]. The majority of the world’s
population is infected with EBV, which is believed to persist
in latently infected B cells and become transmitted to
susceptible individuals via lytic replication in the oral or
genital epithelia [135]. Cytotoxic T cells are important in
controlling and restricting EBV infections in healthy indi-
viduals and infection alone is insufficient for contraction of
EBV-associated malignancies. The ability of BHRF1 to
inhibit death induced by death receptor ligands and activat-
ed monocytes raises the possibility that BHRF1 may assist
in evading the host immune response [125–127].
Immunosuppressed individuals have an increased pro-
pensity for developing EBV-associated lymphomas, how-
ever, the mechanism of tumorigenesis is not understood.
Cellular Bcl-2 can cooperate with c-myc to induce trans-
formation of pre-B and B lymphoid cells [17,120], and it
has been shown that BHRF1 can facilitate transformation
by the adenovirus protein E1A by inhibiting apoptosis [93].
Furthermore, c-myc translocations are observed in African
Burkitt’s lymphoma, which is almost always associated
with EBV [137,138]. However, early studies showed that
EBV with a mutated BHRF1 reading frame was still fully
competent to initiate immortalization of B cells in vitro, and
as stated above, BHRF1 protein expression has not beenconvincingly detected during latency, disfavoring a direct
role for this protein in oncogenesis, at least as revealed in
this model. Latent membrane protein 1 (LMP1) is expressed
by EBV during latency and activates expression of the
cellular bcl-2 gene, perhaps superceding a need for the viral
homolog in tumorigenesis, though there is a lack of corre-
lation between LMP1 expression and cellular Bcl-2 expres-
sion in some cases [139–141]. It may be that BHRF1
contributes indirectly to tumorigenesis by promoting per-
sistent viral replication and thus increasing viral load.
Elevated levels of lytic cycle antigens are detected prior
to the onset of several EBV-associated tumors, suggesting
high viral load correlates with disease [142].
5.3. KSBcl-2
Like EBV, human herpesvirus 8, commonly called
Kaposi’s sarcoma herpesvirus (KSHV), is associated with
the development of human cancers. The virus was first
identified in the Kaposi’s sarcoma (KS) skin lesions of
AIDS patients [143], hence its name, and in addition to
Kaposi’s sarcoma, KSHV is a risk factor in the development
of primary effusion lymphomas and Castleman’s disease
[144,145]. Like its EBV counterpart BHRF1, the Bcl-2
protein of KSHV, KSBcl-2, is expressed early in the lytic
replication cycle and can inhibit apoptosis induced by
several stimuli, including Bax overexpression, viral cyclin
overexpression, and Sindbis virus infection [89,118,146].
KS develops from spindle cells latently infected with
KSHV. Like other gamma herpesviruses, KSBcl-2 RNA is
expressed upon activation of the lytic cycle in cultured cells
but the issue of KSBcl-2 expression at the protein level
needs further exploration. Interestingly, detection of KSBcl-
2 RNA and protein has been reported in KS lesions from
AIDS patients [147,148]. It was suggested that KSBcl-2
protein is widely expressed in spindle cells of late-stage
nodular lesions where the number of lytically infected
spindle cells was assumed to be low, implying possible
expression of KSBcl-2 during latent or persistent infections
[148–151]. In contrast to KS lesions, KSBcl-2 protein was
not detected in stimulated/reactivated primary effusion
lymphoma (PEL) cell lines despite the expression of
KSBcl-2 mRNA [148]. However, the high expression levels
of human Bcl-2 in these PEL cell lines suggest that the
virus may not require expression of its own Bcl-2 protein,
in contrast to the spindle cells in KS tumor nodules where
only low levels of human Bcl-2 expression were reported
[148]. Thus, KSBcl-2 expression may be similar to the
latent phase expression of mouse gHV68 Bcl-2, and if
confirmed, will also emphasize that expression patterns in
vivo can differ from those observed in cell culture models.
However, it is unknown whether KSBcl-2 expression is
causally linked to development of Kaposi’s sarcoma. Nor is
it known if KSBcl-2 is important for maintaining cell
viability during lytic cycle replication or plays a role in
reactivation efficiency.
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The first indication that evading cell destruction was
critical to viral infection came with the discovery of human
adenovirus mutants that exhibit cytopathic effects and
cellular DNA degradation following infection, termed the
cyt/deg phenotype [152–157]. These cell death-inducing
virus mutants produced f 10-fold fewer progeny compared
to wild-type virus and were defective in E1B 19K
[153,157–159], indicating a role for E1B 19K in cell death
suppression and viral replication. Limited sequence homol-
ogy may exist between the highly conserved BH1 domain of
Bcl-2 and the human adenovirus E1B 19K protein [9]. The
functional equivalence of E1B 19K to Bcl-2 in the preven-
tion of cell death during productive infection was demon-
strated by a complementation approach. Overexpression of
Bcl-2 in HeLa cells or CHO cells protected against E1B
19K mutant adenovirus-induced apoptosis [9,160] and a
recombinant adenovirus in which Bcl-2 substituted for the
lack of E1B 19K was successful in suppressing apoptosis
[161]. Like Bcl-2, E1B 19K inhibits cell death induced by
diverse stimuli such as TNF-a, Fas, DNA damaging agents,
ultraviolet radiation, nerve growth factor (NGF) deprivation,
and the tumor suppressor protein p53 [160,162–170]. Also
like cellular Bcl-2, the adenovirus E1B 19K protein can
interact with a broad range of Bcl-2 family members,
including Bax [52,53], Bak [51], Bik [48,49], and Nip
proteins (e.g. BNIP3) [50], although it fails to interact with
Bcl-2-interacting BH3-only proteins Bad [52] and Bid [42].
Although there is not a great deal of data addressing the
molecular mechanism of cell death inhibition by viral Bcl-2
sequence homologs, considerable progress has been made
toward understanding the function of adenovirus E1B 19K
following viral infection or host death receptor signaling.
Surprisingly, although Bax activation occurs both in apo-
ptosis induced by adenovirus lacking E1B 19K and apopto-
sis induced by the cytotoxic cytokine TNF-a, E1B 19K only
targets Bax directly in the TNF-a pathway while inhibition
of virus-induced apoptosis is mediated indirectly through
inhibition of Bak or unknown components of the pathway.
In the TNF-a death receptor signaling pathway, E1B 19K
binds directly to Bax following a conformational change at
the amino terminus of Bax that is likely mediated by tBid
(Fig. 1B), preventing formation of a 500-kDa Bax complex
and apoptosis [43]. A requirement for direct binding of E1B
19K to Bax to inhibit apoptosis was consistent with earlier
suggestions [53,171]; however, in apoptosis induced by
infection with E1B 19K-deficient adenovirus, Bid is not
cleaved and E1B 19K binding to Bax does not occur
[44,45,107], indicating that E1B 19K possesses an alternate
means of suppressing cell death.
Cuconati et al. [44] provided an explanation for the
ability of E1B 19K to block apoptosis in the absence of
Bax interaction by showing that E1B 19K can target Bak
during adenovirus infection and prevent the downstream
activation of Bax. Following infection with adenovirus
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followed by Bak–Bax interaction, and a subsequent shift in
the C-terminal conformational status of Bax. Co-immuno-
precipitation data between E1B 19K and Bak and lack of
Bak–Bax interaction in E1B 19K-proficient virus infection
suggest that E1B 19K anti-apoptotic potency may be linked
directly to its ability to bind Bak following infection.
Nevertheless, the presence of E1B 19K still inhibited
apoptotic DNA fragmentation in adenovirus infection of
Bak-deficient cells [44], indicating that E1B 19K binding to
Bak cannot be its sole means of protection during produc-
tive infection and that other mechanisms of achieving Bax
activation can be recruited in the absence of Bak. Although
Bid is not activated in the death pathway induced by
adenovirus in the absence of E1B 19K, other BH3 proteins
potentially participating in initiating apoptotic events up-
stream of Bax and Bak represent additional possible targets
of E1B 19K.
An independent study using a human epithelial colon
cancer cell line HCT116 found that Bax is required for
efficient adenovirus-induced apoptosis but, in agreement
with the earlier study, binding between Bak but not Bax
and E1B 19K was observed [107]. Interestingly, an N-
terminal truncated version of Bax was generated upon
infection with E1B 19K-deficient adenovirus and the ap-
pearance of this cleavage product was inhibited by the
presence of E1B 19K (i.e. in infection with wild-type
adenovirus). The presence of E1B 19K also reduced the
insertion of the 18-kDa truncated Bax into mitochondrial
membranes. The N-terminal modification of Bax is hypoth-
esized to liberate the C-terminal transmembrane domain
from the hydrophobic cleft [84,172–174], enabling inser-
tion of Bax and release of mitochondrial apoptogenic factors
from the intermembrane space.
In contrast to human epithelial colon cancer HCT116
cells that lack Bax and exhibited reduced apoptosis follow-
ing infection with E1B 19K-defective adenovirus [107],
apoptosis was still observed in Bax-deficient transformed
baby mouse kidney (BMK) cells expressing Bak that are
semipermissive to adenovirus type 5 replication [44]. As
E1B 19K is not effective at protecting adenovirus-infected
mouse cells from TNF-induced death although it is fully
competent to protect human cells from the same death
stimulus [168], it may be that there are variations in the
adenovirus-induced apoptotic pathway in mouse cells vs.
human cells. Alternatively, the difference between the study
using HCT116 cells and the study using BMK cells may
reflect a difference between cell types as Bax and Bak have
been shown to be functionally redundant in many [175] but
not all cell types [176]. Despite these differences, infection
of Bax/Bak doubly-deficient BMK cells with E1B 19K-
deficient adenovirus significantly impaired apoptosis, coin-
ciding with a 10-fold enhancement in viral replication [44].
This finding provides strong experimental support for the
widespread belief that premature apoptosis limits viral
replication. A dramatic decrease in the immunodetection
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proteins in wild-type BMK cells infected with E1B 19K
mutant adenoviruses compared to the wild-type strain indi-
cates that progression to the late stages of the adenovirus life
cycle only occurs when apoptosis is inhibited. Staining for
structural proteins was observed upon infection of BMK
Bax/Bak-deficient cells with the same E1B 19K mutant
viruses, excluding a requirement for an alternate function of
E1B 19K as an explanation for the lack of structural protein
staining in cells infected with the mutant viruses. The study
of the E1B 19K-deficient adenovirus in human epithelial
cells lacking Bax by Lomonosova et al. [107] also revealed
a critical role for E1B 19K in promoting viral replication.
When viral replication was measured by single-step growth
curve analysis, E1B 19K defective viruses exhibited delayed
replication relative to wild-type virus in Bax-positive but not
Bax-negative cells, suggesting that enhanced apoptosis in
E1B 19K mutant virus infection restricts replication. Thus,
the study of adenovirus E1B 19K mutant virus infection in
cells defective in core apoptotic machinery has enabled the
identification of the critical role of apoptosis inhibition in
the virus life cycle. Additionally, it has furthered the
dissection of biochemical pathways utilized by the host cell
to induce apoptosis in response to infection and limit
replication and viral dissemination.
5.5. Viral mitochondria-localized inhibitor of apoptosis
(vMIA)
A Bcl-2 homolog has been identified in an alpha herpes-
virus of turkeys, but no recognizable Bcl-2 homologs are
encoded by h herpesviruses, such as human cytomegalovi-
rus (CMV). Nevertheless, infection of human fibroblasts
with CMV protects against apoptosis induced by adenovi-
ruses lacking anti-apoptotic E1B 19K, demonstrating anti-
apoptotic activity and suggesting that CMV might also
express a protein with Bcl-2 like function [177]. vMIA
encoded by UL37 exon 1 (UL37x1), was uncovered in a
screen of a genomic CMV DNA library for clones able to
rescue HeLa (human epithelial cervix carcinoma) cells from
Fas-induced apoptosis [10]. This 163-amino-acid protein is
encoded by the UL37 gene, along with other alternatively
spliced longer variants. These longer forms, designated
gpUL37M and gpUL37, share the initial 162 amino acids
with pUL37x1 and also possess limited anti-apoptotic
activity, albeit much less robust than pUL37x1. Immuno-
fluorescence and immunoelectron microscopy studies
revealed a predominantly mitochondrial outer membrane
localization for vMIA, prompting the redesignation of
pUL37x1 as vMIA [10]. An antisense oligonucleotide
approach has demonstrated that the UL37 gene is required
for human CMV DNA replication [178], however, whether
the anti-apoptotic activity of vMIA is responsible for this
requirement is currently under investigation.
There is no amino acid sequence similarity between
vMIA and Bcl-2 family members, and vMIA interactionswith Bcl-2 family members have yet to be published. Two
domains within vMIA are important for its ability to block
cell death, one near the N-terminus (amino acids 5–34) that
is required for mitochondrial targeting and the second
spanning amino acids 118–147 that is of unknown function
but may be important for the observed interaction between
vMIA and the ANT [179,180]. The interaction of vMIA
with the ANT may be protective by inhibiting mitochondrial
permeability transition and cytochrome c release or by
regulating ADP/ATP exchange as has been proposed for
Bcl-2 [63,67,181].
vMIAwas also found to alter mitochondrial morphology.
Expression of a dominant-negative version of the mitochon-
drial fission protein Drp-1 inhibits mitochondrial fragmen-
tation during apoptosis, delays cytochrome c release, and
delays cell death [182,183], prompting investigation of
changes in mitochondrial morphology during apoptosis. A
caspase-8 cleavage product of Bcl-2-associated protein-31
(BAP31) at the ER promotes ER-to-mitochondria calcium
signaling that recruits Drp1 to mitochondria [184]. The
recruitment of Drp1 leads to mitochondrial fission and
sensitization to tBid-mediated cytochrome c release. Sur-
prisingly, examination of mitiochondrial morphology fol-
lowing CMV-infection of human fibroblasts revealed a
fragmentation of mitochondrial networks that is apparently
mediated by vMIA [185]. Paradoxically, vMIA-induced
mitochondrial fragmentation is strikingly similar to that
observed during apoptosis. In contrast to what was expected
from the correlation between mitochondrial fission and
tBid-mediated death, CMV-infected cells with fragmented
mitochondria were protected against Fas-induced death. A
68-amino-acid peptide encompassing the two identified
functional domains of vMIA was fully competent to protect
cells and also to induce the fragmented mitochondrial
phenotype, suggesting a link between mitochondrial fission
and anti-apoptotic activity [185]. Cells with fragmented
mitochondria expressing the highest levels of vMIA dis-
played fainter Mitotracker RedR staining compared to cells
with lower vMIA content and more reticular mitochondrial
morphology [185]. As Mitotracker RedR uptake is depen-
dent on mitochondrial membrane potential, this suggests
that mitochondria that underwent fission have a reduced
membrane potential. It is therefore possible that a lowered
mitochondrial membrane potential contributes to protection
by vMIA since there is an inverse relationship between
membrane potential and the production of reactive oxygen
species [186]. The functional role of mitochondrial frag-
mentation in apoptosis is still unclear, however, and it is
possible that premature or altered fission may impede the
apoptotic process.6. Conclusions
It has been widely hypothesized that viral Bcl-2 homo-
logs serve a vital role in the virus life cycle by inhibiting the
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cation, allowing completion of the replication cycle and
favoring the spread of progeny virus. Although it appears
that the adenovirus functional Bcl-2 homolog E1B 19K
indeed functions in this manner, the limited evidence on the
function of g-herpesvirus Bcl-2 proteins does not support a
similar role. This may be due to the redundancy of apoptosis
inhibitors encoded by many of the viruses that contain Bcl-2
homologs or, alternatively, viral Bcl-2 proteins may partic-
ipate in the virus life cycle in more complex ways. A study
of murine gHV68 Bcl-2 demonstrates a role for this protein
in reactivation from latency, persistent replication, and
chronic disease, indicating that viral Bcl-2 proteins may
indeed play a significant role in virulence. It may turn out
that different viruses need Bcl-2 homologs to block apopto-
sis in different aspects of their life cycle and that there is no
one unifying hypothesis that fits all viral Bcl-2 proteins.
Undoubtedly, concerning the role of viral Bcl-2 homologs,
we still have much to learn.References
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